SLLK, Control Peptide for TSP1 Inhibitor (TFA) is a control peptide for LSKL, which is a Thrombospondin (TSP-1) inhibitor.

(-)-CXL017 is a small molecule that has selective cytotoxicity toward MDR cancer cell lines in vitro, through inhibition of the sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA) with IC50 of 13.5 uM.

Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a glucagon-like peptide-1 (GLP-1R)/glucagon receptor GCGR co-agonist. Mazdutide has safety and tolerability, and it can be used for research in obesity and type 2 diabetes (T2D).

Palmitoyl tripeptide-38 is a bioactive peptide with anti-aging effect .

(Rac)-NRL-1049 is the racemic mixture of NRL-1049 (BA-1049 (free base)) (HY-162596). NRL-1049 is an orally available and selective ROCK2 inhibitor with IC50 values of 0.59 µM for ROCK2 and 26 µM for ROCK1, respectively. NRL-1049 modulates ROCK signaling, preserves blood-brain barrier integrity, reduces edema, seizures and hemorrhage, and alleviates cerebral cavernous malformation lesion burden. NRL-1049 can be used for the study of acute brain injury, ischemic stroke, and cerebral cavernous malformations.

A40926, the precursor of Dalbavancin, is a second-generation glycopeptide antibiotic. A40926 inhibits gram-positive bacteria, and is very active against Neisseria gonorrhoeae.

PTC-258 2HCl is a specific and orally active splicing modulator of Elongator complex protein 1 gene (ELP1). PTC258 increases the expression of ELP1 in vitro and in vivo. PTC258 is well tolerated in mouse model.

(S,R,S)-AHPC-Me-C8-NH2 is a novel PROTAC building block.

(S,R,S)-AHPC-Me-C3-NH2 is a novel PROTAC building block.

(S,R,S)-AHPC-Me-C2-NH2 is a novel PROTAC building block.

(S,R,S)-AHPC-Me-C1-NH2 is a novel PROTAC Building block.

DZD9008 is an oral, potent, irreversible, wild type-selective EGFR TKI against EGFR or HER2 Exon20ins and other mutations.

ReACp53 is a cell-penetrating peptide,designed to inhibit p53 amyloid formation.

Compoud 18 (AEP inhibitor) is first orthosteric, selective, orally bioavailable, and brain penetrant inhibitor with IC50 of 7.8 nM against asparagine endopeptidase (AEP) with an irreversible binding mode.

Fura-2 AM is a membrane permeable, intracellular, UV light-excitable and ratiometric fluorescent Ca2+ (calcium ion) indicator. Fura-2 AM crosses cell membranes and is converted to Fura-2 (HY-D0110A) via cellular esterases. Fura-2 AM can be used to detect calcium in cells.

SMPH Crosslinker is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.

CVL1 (C24), also known as VitE-C4DE-Pip-S, is a vitamin E-derived ionizable lipid developed for lipid nanoparticle-mediated delivery of mRNA and other nucleic acids developed by CureVac. It features two hydrophobic α-tocopherol moieties connected to a bis-piperidine ionizable core through biodegradable succinate ester linkages, while a central thioether-containing spacer provides additional structural flexibility. CVL1 can be incorporated into LNP formulations to support nucleic acid encapsulation, cellular uptake, and intracellular delivery. CureVac has investigated CVL1-containing LNPs for mRNA expression in immune-related tissues and cells, including the spleen, lymph nodes, and antigen-presenting cells, making it a valuable research lipid for mRNA vaccines, cancer immunotherapy, and other nucleic acid delivery applications.

MoChol is a cationic cholesterol derivative used as a membrane component in charge-reversible amphoteric nanoliposomes. It has been incorporated with CHEMS, DOPE and POPC into liposomal formulations for the delivery of anti-BCL-2 antisense oligonucleotides.

Rovadicitinib is a first-in-class oral small-molecule inhibitor of JAK/Rho‑associated kinases (ROCK), exhibiting potent inhibitory activity against JAK1, JAK2, ROCK1, ROCK2, and TYK2.

Prifemilast is a phase 3 clinical-stage selective inhibitor of PDE4B.

Compound 183c is a potent inhibitor of histone lysine-specific demethylase 2A (KDM2A, FBXL11, or JHDM1A).

Balovaptan (RG7314, RG-7314) is a potent, selective vasopressin-1 receptor antagonist..

VU6053371 (BI03738809) is a selective positive allosteric modulator (PAM) of metabotropic glutamate receptor subtype 3 (mGlu3). It is blood–brain barrier penetrant and orally active, exhibits selectivity for mGlu3 over other mGlu receptor subtypes, and can be used in research on schizophrenia, Alzheimer's disease, and other types of dementia and cognitive disorders.

GL-4512 is a preclinical small-molecule direct modulator of leukocyte immunoglobulin-like receptor B4 (LILRB4, also known as ILT3/CD85k). It binds to immobilized LILRB4 protein, inhibits the LILRB4–SCG2 interaction, and suppresses LILRB4-mediated immunosuppressive signaling pathways associated with tumor immune evasion.

TTP-3 is an asymmetric Ugi-derived ionizable lipid developed specifically for pulmonary delivery of structured suppressor tRNA cargo. Its architecture combines a dimethylaminopropyl ionizable headgroup, two amide-containing linkages, and chemically distinct hydrophobic tails. Selected from a 1,000-member lipid library, TTP-3 showed the strongest suppressor-tRNA delivery in a cystic-fibrosis-relevant air–liquid interface model containing artificial mucus. An optimized formulation containing TTP-3, DOPE, β-sitosterol, and C14-PEG2000 produced approximately 38-fold higher functional pulmonary reporter expression than MC3 following intratracheal administration in mice. TTP-3 LNPs preferentially delivered tRNA to airway epithelial cells, including ciliated, club, ionocyte, and basal progenitor populations. When combined with chemically modified suppressor tRNAs, the platform restored CFTR expression and function in cellular, mouse, and patient-derived organoid models. TTP-3 remains a preclinical research lipid, and further optimization is required for aerosol delivery, repeat dosing, and clinical translation.

CICL1 (L829)​​ is a ​​novel ionizable cationic lipid​​ specifically engineered for ​​targeted lipid nanoparticles (tLNPs)​​ that enables efficient in vivo delivery of mRNA payloads to ​​CD8+ T cells​​. Designed to overcome limitations of conventional LNPs, CICL-1 (L-829)​​significantly ​​reduces off-target delivery to the liver​​ and exhibits ​​rapid clearance​​ compared to benchmark lipids like ALC-0315, while demonstrating ​​enhanced biodegradability and tolerability​​ in rodent and primate models. When incorporated into CD8-targeted tLNPs, CICL 1 (L829 enables ​​preferential transfection of CD8+ T cells​​ over other immune subsets, facilitating the generation of functional ​​anti-CD19 or anti-CD20 CAR T cells directly *in vivo​​*. These tLNP-engineered CAR T cells mediate ​​rapid, deep B-cell depletion​​ in humanized mice and cynomolgus monkeys, with repopulating B cells exhibiting a naïve phenotype suggestive of immune reset. By eliminating the need for ex vivo manufacturing or lymphodepleting chemotherapy, the L829-tLNP platform represents a ​​safer, scalable approach​​ for accessible CAR T therapy in oncology and autoimmune diseases.

C14-306 is a rationally designed ionizable lipid for brain targeting delivery, characterized by a linear 3,3'-diamino-N-methyldipropylamine (306) core conjugated with tetradecyl (C14) tails. This specific architectural configuration, synthesized via epoxide ring-opening amination, yields a molecular structure that optimally balances hydrophobic character and protonation capacity. The C14 alkyl chains enhance membrane integration and LNP stability, while the multiamine core facilitates efficient mRNA complexation and pH-dependent endosomal disruption. When formulated into LNPs with standard helper lipids (DOPE, cholesterol, DMG-PEG2000), C14-306-based nanoparticles exhibit favorable physicochemical properties, including a monodisperse size distribution near 110 nm and high mRNA encapsulation efficiency (>84%). High-throughput in vivo barcoding screening identified C14-306 LNPs as lead candidates for brain delivery, demonstrating a significant tropism for neuronal cells over liver tissue. In validation studies, LNPs incorporating C14-306 achieved a 6.9-fold increase in luciferase mRNA transfection in the mouse brain compared to the SM-102 benchmark, coupled with a substantial reduction in hepatic off-target expression. Flow cytometry confirmed preferential transfection of NeuN+ neurons, and safety assessments indicated no significant blood-brain barrier compromise or induction of systemic inflammation. The efficacy of C14-306 is attributed to its tailored pKa, promoting extended circulation and enhanced endosomal escape within brain cells. C14-306 represents a promising platform for systemic mRNA therapeutics targeting neurological disorders.

NP213 is a rapidly acting, novel, first-in-class synthetic antimicrobial peptide (AMP), has anti-fungal activities. NP213 targets the fungal cytoplasmic membrane and plays it role via membrane perturbation and disruption. NP213 is effective and well-tolerated in resolving nail fungal infections.

NGI-1 derivative C-19 is a specific, small-molecule inhibitor of oligosaccharyltransferase (OST) catalytic subunit STT3B, without effect on STT3A.